Skip to main content

1 Result(s)

within Yungpo Bernard Su Remove this filter

and

  1. No Access

    Article

    A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors

    Based on our mouse xenograft model demonstrating that intermittent high-dose gefitinib sensitizes tumors to subsequent treatment with taxanes, we initiated this phase I trial to explore docetaxel in combinatio...

    Matthew G. Fury, David B. Solit, Yungpo Bernard Su… in Cancer Chemotherapy and Pharmacology (2007)